Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
NCT05086081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28389
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Acute Coronary Syndrome
Interventions
- DRUG
-
Ticagrelor 90mg
Any ticagrelor dispensing claim is used as the exposure group
- DRUG
-
Prasugrel 10mg
Any prasugrel dispensing claim is used as the reference group
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-10
- Primary Completion
- 2021-09-10
- Completion
- 2021-09-10
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
NCT05183178 ·Status: RECRUITING ·Phase: PHASE4
-
Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients
NCT04861363 ·Status: UNKNOWN
-
Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan
NCT03615846 ·Status: UNKNOWN
-
Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS
NCT03881943 ·Status: COMPLETED ·Phase: PHASE4
-
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets
NCT03005704 ·Status: UNKNOWN ·Phase: NA
-
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
NCT04492423 ·Status: COMPLETED
-
Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction
NCT05744804 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
NCT05093790 ·Status: COMPLETED ·Phase: PHASE2
-
Outcomes in UK ACS Patients Prescribed Ticagrelor
NCT03058601 ·Status: COMPLETED
-
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
NCT04240834 ·Status: RECRUITING ·Phase: PHASE4
-
Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients
NCT02929888 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
NCT05476991 ·Status: RECRUITING ·Phase: PHASE3
-
Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction
NCT03387826 ·Status: COMPLETED ·Phase: PHASE4
-
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
NCT01611272 ·Status: COMPLETED
-
Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)
NCT06916520 ·Status: RECRUITING ·Phase: PHASE4
-
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
NCT01994720 ·Status: COMPLETED ·Phase: PHASE3
-
ARISE - Aggressive Reduction of Inflammation Stops Events
NCT00066898 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
NCT05418166 ·Status: UNKNOWN
-
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
NCT04753372 ·Status: COMPLETED
-
Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion
NCT04014803 ·Status: RECRUITING ·Phase: PHASE4
-
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
NCT04739384 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
NCT05986968 ·Status: RECRUITING ·Phase: NA
-
A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome
NCT02293395 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
NCT05730621 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
NCT00548587 ·Status: COMPLETED ·Phase: PHASE2